Show simple item record

dc.contributor.authorde Wit, S
dc.contributor.authorManicone, M
dc.contributor.authorRossi, E
dc.contributor.authorLampignano, R
dc.contributor.authorYang, L
dc.contributor.authorZill, B
dc.contributor.authorRengel-Puertas, A
dc.contributor.authorOuhlen, M
dc.contributor.authorCrespo, M
dc.contributor.authorBerghuis, AMS
dc.contributor.authorAndree, KC
dc.contributor.authorVidotto, R
dc.contributor.authorTrapp, EK
dc.contributor.authorTzschaschel, M
dc.contributor.authorColomba, E
dc.contributor.authorFowler, G
dc.contributor.authorFlohr, P
dc.contributor.authorRescigno, P
dc.contributor.authorFontes, MS
dc.contributor.authorZamarchi, R
dc.contributor.authorFehm, T
dc.contributor.authorNeubauer, H
dc.contributor.authorRack, B
dc.contributor.authorAlunni-Fabbroni, M
dc.contributor.authorFarace, F
dc.contributor.authorDe Bono, J
dc.contributor.authorIJzerman, MJ
dc.contributor.authorTerstappen, LWMM
dc.date.accessioned2019-02-20T08:15:44Z
dc.date.issued2018-11-02
dc.identifier.citationOncotarget, 2018, 9 (86), pp. 35705 - 35716
dc.identifier.issn1949-2553
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3071
dc.identifier.eissn1949-2553
dc.identifier.doi10.18632/oncotarget.26298
dc.description.abstractThe presence of high expressing epithelial cell adhesion molecule (EpCAM high ) circulating tumor cells (CTC) enumerated by CellSearch ® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAM low CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAM high and EpCAM low CTC using CellSearch, followed by microfiltration of the EpCAM high CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had ≥5 EpCAM high CTC and 28% had ≥5 EpCAM low CTC. For breast cancer patients, 32% had ≥5 EpCAM high CTC and 36% had ≥5 EpCAM low CTC. 70% of prostate cancer patients and 64% of breast cancer patients had in total ≥5 EpCAM high and/or EpCAM low CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ≥5 EpCAM high CTC had shorter overall survival versus those with <5 EpCAM high CTC ( p = 0.000). However, presence of EpCAM low CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.
dc.formatElectronic-eCollection
dc.format.extent35705 - 35716
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleEpCAM<sup>high</sup> and EpCAM<sup>low</sup> circulating tumor cells in metastatic prostate and breast cancer patients.
dc.typeJournal Article
dcterms.dateAccepted2018-10-25
rioxxterms.versionofrecord10.18632/oncotarget.26298
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-11-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncotarget
pubs.issue86
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
icr.researchteamCancer Biomarkersen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorRescigno, Pasqualeen
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorCrespo, Mateusen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0